drugset / Trial / NCT07662044

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

NCT07662044

Phase 3 Recruiting 800 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

Timeline

Start
2026-07-06
Primary completion
2028-07-14
Completion
2028-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule Oral
Subject Elecoglipron Unknown Oral